Foscarnet Decreases Human Immunodeficiency Virus RNA

Kaiser, Laurent; Perrin, Luc; Hirschel, Bernard; Furrer, H.; Overbeck, Jan von; Olmari, M.; Yerly, Sabine

doi:10.1093/infdis/172.1.225

Cited by 23 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in both of our cases, CMV reactivation became evident at some point, but the meaning in this context remains unclear. Foscarnet further possesses anti-retroviral activity that might have contributed to the successful treatment [10].…”

Section: Discussionmentioning

confidence: 99%

Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

Schneider

Ruhnke

Delecluse

et al. 2000

Annals of Hematology

View full text Add to dashboard Cite

Epstein-Barr virus (EBV)-associated lymphoproliferative disorders frequently develop in patients with acquired immunodeficiency syndrome (AIDS). The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective. However, we report about two AIDS patients with EBV-associated lymphoproliferative disorders not responding to a standard chemotherapy, who achieved complete tumour regression after virustatic therapy with foscarnet.

show abstract

Section: Discussionmentioning

confidence: 99%

Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

Schneider

Ruhnke

Delecluse

et al. 2000

Annals of Hematology

View full text Add to dashboard Cite

show abstract

“…Among AIDS patients receiving FOS treatment for CMV disease, several studies have reported an inhibitory effect on plasma HIV load. 7,8 Furthermore, FOS represents a therapeutic option for patients infected with late-stage HIV infection and multidrug-resistance. The efficiency of this molecule used as salvage therapy has been recently underlined by several studies, with a markedly decrease of plasma HIV load and an improvement of immunological status.…”

Section: Why This Case Is Importantmentioning

confidence: 99%

“…Thus, in previous studies reporting the evaluation of FOS on HIV replication in AIDS patients exhibiting different types of herpesvirus active infections (i.e., CMV, herpes simplex virus [HSV], varicella-zoster virus), the question of the possible emergence of herpesvirus resistance to antivirals has not been addressed. 7,8 In more recent studies highlighting the efficacy of FOS salvage therapy in patients harboring multidrug-resistant HIV infection, the concomitant herpesvirus infections were not mentioned. 9-11 Conversely, the possible impact of antivirals on the emergence of HIV resistance constitutes a matter of concern.…”

Section: Other Similar and Contrasting Cases In The Literaturementioning

confidence: 99%

Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection

Boutolleau

Canestri²,

Burrel

et al. 2012

Journal of Clinical Virology

View full text Add to dashboard Cite

“…62 In addition to the anti-CMV effects, foscarnet, and possibly ganciclovir, also have an inhibitory effect on HIV. 63,64 A number of open-label trials of ganciclovir for HIV-infected patients with gastrointestinal CMV disease have demonstrated clinical improvement in %75% of patients. 65±68 Openlabel trials of foscarnet have yielded comparable results.…”

Section: Cytomegalovirusmentioning

confidence: 99%

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

Wilcox

Mönkemüller

1997

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Although there have been dramatic strides in the therapy of human immunodeficiency virus infection over the last few years, the number of infected people world‐wide is tremendous and, at least in developing countries, continues to expand. Complications which involve the gastrointestinal tract are common in these patients, because the gut is a major site for involvement by opportunistic infections and neoplasms in patients with the acquired immunodeficiency syndrome. It is important to recognize the clinical spectrum of gastrointestinal diseases, as well as the appropriate and most cost‐effective diagnostic strategies, as therapies for a number of these disorders are both widely available and highly effective. This review summarizes the major gastrointestinal infections which are seen in patients with the acquired immunodeficiency syndrome, and their treatment.

show abstract

Foscarnet Decreases Human Immunodeficiency Virus RNA

Cited by 23 publications

References 14 publications

Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet

Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection

The therapy of gastrointestinal infections associated with the acquired immunodeficiency syndrome

Contact Info

Product

Resources

About